SCHEMBL5037019

SCHEMBL5037019

CC(C)c1ccc(S(=O)(=O)Nc2cc[c]cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.58
ALDH1A1 P00352 3/20 0.58
LMNA P02545 2/20 0.58
PKM P14618 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
PGR P06401 1/20 0.54
POLB P06746 1/20 0.52
TRIM24 O15164 1/20 0.51
BRD1 O95696 1/20 0.51
BRPF1 P55201 1/20 0.51
GHSR Q92847 1/20 0.51
THRB P10828 1/20 0.49
CES1 P23141 1/20 0.49
DRD2 P14416 3/20 0.48
DRD3 P35462 3/20 0.48
KCNH2 Q12809 3/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040134 0.81 ALDH1A1 (0.50) MAPTALDH1A1LMNAPKMSMN1; SMN2
SCHEMBL7572277 0.81 CES1 (0.76) MAPTALDH1A1LMNAPKMSMN1; SMN2
SCHEMBL11976998 0.81 ALDH1A1 (0.64) MAPTALDH1A1LMNAPKMSMN1; SMN2
SCHEMBL10528973 0.81 KMT2A (0.68) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL4142277 0.81 CES1 (0.75) MAPTALDH1A1PGRCES1
SCHEMBL3277692 0.81 CA12 (0.68) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL95042 0.80 MAPT (0.62) MAPTALDH1A1LMNAPKMSMN1; SMN2
SCHEMBL7176650 0.80 LMNA (0.62) MAPTALDH1A1LMNAPKMSMN1; SMN2
SCHEMBL7580346 0.80 KDM1A (0.63) MAPTALDH1A1LMNAPKMSMN1; SMN2
SCHEMBL13995037 0.79 PGR (0.69) MAPTALDH1A1LMNAPKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250325-B1 PHENANTHRIDINE-N-OXIDES NYCOMED GMBH (DE) 2008-05-07 EP disclosed
US-6630483-B2 Phenanthridine-N-oxides ALTANA PHARMA AG (DE) 2003-10-07 US disclosed
US-20030105123-A1 For therapy of respiratory system disorders ALTANA PHARMA AG (DE) 2003-06-05 US disclosed
EP-1250325-A1 PHENANTHRIDINE-N-OXIDES ALTANA Pharma AG (DE) 2002-10-23 EP disclosed
EP-0889886-B1 NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION ALTANA PHARMA AG (DE) 2002-09-18 EP disclosed
WO-2001051470-A1 PHENANTHRIDINE-N-OXIDES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2001-07-19 WO disclosed
US-6127378-A A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105123-A1 For therapy of respiratory system disorders CHRM3, CYP11B1, CYP11B2 MAPT 4639/4885ALDH1A1 1029/4885LMNA 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.